Please check your internet connection and try again.
# Meftal Spas
## Overview
Meftal Spas is a combination product containing mefenamic acid (a nonsteroidal anti-inflammatory drug, NSAID) and dicyclomine hydrochloride (an anticholinergic antispasmodic).
## Primary Indications
* Symptomatic relief of abdominal pain and spasms associated with irritable bowel syndrome (IBS).
* Relief of menstrual pain (dysmenorrhea).
## Adult Dosing
* **Irritable Bowel Syndrome:** 1 tablet (250 mg mefenamic acid / 20 mg dicyclomine) orally up to 3 times daily as needed for abdominal pain and spasms.
* **Dysmenorrhea:** 1 tablet (250 mg mefenamic acid / 20 mg dicyclomine) orally every 8 hours, starting with the onset of pain. Do not exceed 3 tablets in 24 hours.
## Pediatric Dosing
Dosing for Meftal Spas in pediatric patients has not been established. Mefenamic acid is generally not recommended for use in children under 14 years of age.
## Dose Adjustments
* **Renal Impairment:** Caution advised. Mefenamic acid is renally excreted.
* **Hepatic Impairment:** Caution advised.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Inflammatory bowel disease, paralytic ileus, severe constipation, pyloric or duodenal obstruction, achalasia, glaucoma, obstructive uropathy, prostatic hypertrophy, or myasthenia gravis due to the anticholinergic effects of dicyclomine.
* Coronary artery bypass graft (CABG) surgery.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal pain, constipation, diarrhea, dizziness, drowsiness, headache, blurred vision, dry mouth.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation; renal failure; hepatotoxicity; cardiovascular thrombotic events (myocardial infarction, stroke); hypersensitivity reactions (including anaphylaxis); Stevens-Johnson syndrome, toxic epidermal necrolysis; exacerbation of asthma. Anticholinergic effects can include urinary retention, tachycardia, and confusion.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **Other NSAIDs (including aspirin):** Increased risk of gastrointestinal toxicity, renal toxicity.
* **SSRIs/SNRIs:** Increased risk of gastrointestinal bleeding.
* **Diuretics, ACE inhibitors, ARBs:** Reduced antihypertensive effect, increased risk of renal impairment.
* **Lithium:** Increased lithium levels.
* **Methotrexate:** Increased methotrexate toxicity.
* **Anticholinergics:** Additive anticholinergic effects.
* **Antacids:** May decrease absorption of dicyclomine.
## Monitoring
* **GI Bleeding:** Monitor for signs and symptoms of gastrointestinal bleeding (e.g., melena, hematemesis).
* **Renal Function:** Monitor renal function, especially in patients with pre-existing renal disease or those at risk.
* **Hepatic Function:** Monitor liver function tests.
* **Blood Pressure:** Monitor blood pressure, particularly with chronic NSAID use.
* **Anticholinergic Effects:** Monitor for signs of excessive anticholinergic effects (e.g., dry mouth, urinary retention, blurred vision, confusion).
## Clinical Pearls
* Meftal Spas should be used at the lowest effective dose for the shortest duration necessary to control symptoms.
* Mefenamic acid carries a risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which may increase with duration of use.
* Mefenamic acid can cause serious gastrointestinal bleeding, ulceration, and perforation. The risk is higher in elderly patients and those with a history of peptic ulcer disease.
* The anticholinergic component (dicyclomine) can cause drowsiness and blurred vision; patients should exercise caution when driving or operating machinery.
* Avoid concurrent use of other NSAIDs or salicylates.
* For dysmenorrhea, treatment should begin with the onset of pain.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and local protocols for complete details and to ensure patient safety.*
